Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2021 Jun 21;14(7):e007600. doi: 10.1161/CIRCOUTCOMES.120.007600

Table 5.

Patient or charted reasons for non-adherence

Reason Apixaban % of 1006 Rivaroxaban % of 415
Financial or prior authorization difficulties 15 1.5% 5 1.2%
Perceived side effect other than bleeding 13 1.3% 3 0.7%
Bleeding as perceived by patient 11 1.1% 3 0.7%
Prescription not filled/patient choice 7 0.7% 4 1.0%
Worsened clot symptoms without new diagnosis 2 0.2% 1 0.2%
Other or unknown 35 3.5% 14 3.4%
Total 83 8.3% 30 7.2%